MENU
Advertisement
Show Filters
Refine by Content Type
Refine by Year
Sort By:
Choose Sites to Search:
Liver Embolization
Panelists: Aravind Arepally, MD, FSIR; Tobias F. Jakobs, MD; and Mark Westcott, MD
ABK Biomedical’s Easi-Vue Embolic Microspheres Cleared by FDA to Treat Arteriovenous Malformations and Hypervascular Tumors
September 12, 2022—ABK Biomedical, Inc. announced FDA 510(k) clearance of the company’s Easi-Vue embolic microspheres for the treatment of patients with arteriovenous malformations and hypervascular tumors.
ABK Biomedical’s Eye90 Microspheres Granted FDA Breakthrough Device Designation
December 5, 2023—ABK Biomedical, Inc. announced that its Eye90 microspheres have been granted Breakthrough Device designation by the FDA.
ABK Biomedical Gains IDE Approval for Pivotal Study of Eye90 Microspheres to Treat Hepatocellular Carcinoma
May 30, 2023—ABK Biomedical, Inc. announced it has received Investigational Device Exemption approval from the FDA to commence a multicenter pivotal clinical study in the United States for the company’s imageable Eye90 microspheres yttrium-90 (Y90) radioembolization therapy.
Practical Uses of Cryoplasty
A look at some of the effective applications of this nonsurgical treatment option.
By Pranab Das, MD; Santosh K. Koshy, MD; Robert S. Dieter, MD, RVT; and Aravinda Nanjundappa, MD, RVT
